View More View Less
  • 1 Faculdade de Medicina de Ribeirão Preto, Departamento de Neurociências e Ciências do Comportamento, Hospital das Clínicas, Universidade de São Paulo, Ribeirão Preto, Brazil
  • | 2 National Institute of Science and Technology – Translational Medicine, Ribeirão Preto, Brazil
  • | 3 ICEERS Foundation (International Center for Ethnobotanical Education, Research and Services), Barcelona, Spain
  • | 4 The Enyart Group, Los Angeles, CA, USA
Open access

Background and aims

Aphantasia (“blind imagination”) is a poorly described condition with an uncertain etiology, characterized by reduced or lack of voluntary visual imagery. Preliminary evidence in humans suggests that hallucinogenic or psychedelic drugs that act as agonists of cortical 5-HT2A receptors [lysergic acid diethylamide, psilocybin, and dimethyltryptamine (DMT)] enhance visual imagery.

Methods

Interview and description of the case are presented in this study.

Results

A man self-diagnosed with long-lasting aphantasia that he attributed to a traumatic separation from his father when he was young and to a difficult relationship with him described sustained improvements in his visual imagery following ingestion of a single dose of the South American botanical hallucinogen ayahuasca, which is rich in DMT. Although improvements were modest, they were sustained and significative for the subject.

Conclusions

It is suggested that the described improvements were possibly attributed to biological and psychological processes, including stimulation of cortical 5-HT2A receptors, subsequent increased activity in the visual cortex, enhanced imaginative and imagery capacities, and psychosomatic resolution of a previous psychological trauma. Further trials could elucidate the role of 5-HT2A agonists, especially ayahuasca, in aphantasia.

Abstract

Background and aims

Aphantasia (“blind imagination”) is a poorly described condition with an uncertain etiology, characterized by reduced or lack of voluntary visual imagery. Preliminary evidence in humans suggests that hallucinogenic or psychedelic drugs that act as agonists of cortical 5-HT2A receptors [lysergic acid diethylamide, psilocybin, and dimethyltryptamine (DMT)] enhance visual imagery.

Methods

Interview and description of the case are presented in this study.

Results

A man self-diagnosed with long-lasting aphantasia that he attributed to a traumatic separation from his father when he was young and to a difficult relationship with him described sustained improvements in his visual imagery following ingestion of a single dose of the South American botanical hallucinogen ayahuasca, which is rich in DMT. Although improvements were modest, they were sustained and significative for the subject.

Conclusions

It is suggested that the described improvements were possibly attributed to biological and psychological processes, including stimulation of cortical 5-HT2A receptors, subsequent increased activity in the visual cortex, enhanced imaginative and imagery capacities, and psychosomatic resolution of a previous psychological trauma. Further trials could elucidate the role of 5-HT2A agonists, especially ayahuasca, in aphantasia.

Introduction

Visual imagery is usually experienced by humans in memory processes, day-dreaming/mind-wandering, dreaming, imagination, and creativity. Some techniques, such as breathing exercises, imagery training, and psychoactive drugs, can and have been used to stimulate visual imagery and creativity (Schultes & Hofmann, 1992). The neural basis of voluntary imagery involves activation of frontal and parietal brain regions associated with memory and executive functions and of occipital regions related to visual processing (Zeman, Dewar, & Della Sala, 2015).

Aphantasia is a term proposed by Zeman et al. (2015) to describe a rarely recognized phenomenon characterized by “reduced or absent voluntary imagery.” The neural basis of this apparently rare condition is not well-understood but seems to involve deficits of information processing in the same brain regions that are involved in visual imagery, i.e., frontoparietal and occipital cortices. Moreover, deficits in visual memory and other cognitive functions also seem to be involved (Zeman et al., 2015; Zeman, Dewar, & Della Sala, 2016). Some authors have suggested that aphantasia may have a psychological origin, instead of an organic basis (de Vito & Bartolomeo, 2016). Consistent with this perspective, aphantasia is often associated with depressive, anxious, and dissociative disorders. Thus, several possible interacting factors may contribute to this condition. To the best of the authors’ knowledge, there are no treatments for this condition.

Ayahuasca is a psychoactive botanical preparation with a long history of ritual and therapeutic uses in the northwestern Amazon. It is prepared by the decoction of the stalks of the harmine-rich liana Banisteriopsis caapi together with the leaves of the Psychotria viridis bush, which contains dimethyltryptamine (DMT; Schultes & Hofmann, 1992). Harmine and related beta-carbolines are reversible inhibitors of monoamine oxidase, and DMT acts as an agonist at cortical 5-HT2A/2C/1A receptors. Open-label and controlled studies showed that a single ayahuasca dose was associated with significant reductions in depressive symptoms in patients with treatment-resistant depression (Palhano-Fontes et al., 2018; Sanches et al., 2016). Interestingly, ayahuasca – as other agonists of cortical 5-HT2A/2C/1A receptors, such as lysergic acid diethylamide (LSD) and psilocybin – enhances visual imagery (Carhart-Harris et al., 2016; de Araujo et al., 2012; dos Santos, Osório, Crippa, & Hallak, 2016; Roseman et al., 2016).

In October 2016, the authors were contacted by a 39-year-old man, Scotty Enyart (SE), who claimed that ayahuasca improved his aphantasia.

Case Presentation

SE believed that his symptoms began early in his life, since he recalls from an early age that his “inner experiences were different from others.” According to SE, he was diagnosed with poor visual imagery in elementary, middle, and high schools. For instance, reading never evoked visual imagery and at the age of 16, he could not visualize the patterns of words, and he described his spelling ability as: “was that of an eleven-year-old and my reading comprehension was even more delayed than my spelling.” Moreover, during this period, he had low self-esteem and had to receive special education classes and extended hours of practicing tasks, including typing: “Looking back at my life it became clear that my spelling ability developed to an age appropriate level only when I learned how to type. A component of being a good speller is remembering patterns of words; so, when someone can’t recall how to spell a word they will visualize the word. Learning how to type allowed me to understand words through touch, so if I can’t recall a word I will use my fingers, muscle memory, to feel the word out.”

At that time, in the mid 1990s, there was not a formal diagnosis of aphantasia since the term had not been proposed yet. SE first noticed that he had aphantasia in 2001, during a cognitive psychology course in his undergraduate program, when he was 24 years old: “The professor asked us students to close our eyes and recall an image of a clock. Once we identified an image he then asked us to draw that image on a piece of paper. The other students began to draw detailed clocks. I closed my eyes several times trying to bring forth an image of a clock, yet nothing came.” He self-diagnosed his aphantasia in 2015 after watching a BBC special report on a man with the same diagnosis (Gallagher, 2015). SE explained to us that: “When I close my eyes I cannot see my wife’s face, I cannot see my children. If I close my eyes and think about my wife or kids I sense physical space, facial features that are unique to my wife and kids are not seen but the feeling of these features is there. I can sense my emotional attachment to them deeply. I can hear their voices, I can sense their touch, but I cannot see them.” Moreover, he told us that he does not see anything in his dreams: “My dreams are felt spatially and emotionally but the visual doesn’t exist. When dreaming about being chased by a monster I can feel I am moving through space and I experience intense fear, but the monster has no form, it is a terrifying felt presence that is coming after me.

SE reported that when he was a teenager, he experimented with hallucinogens/psychedelics, such as LSD and psilocybin, but according to him, these experiences were “external” with visual effects experienced only with opened eyes: “The settings were with others walking around during the day hours watching walls melt in public places or seeing people with distorted faces pass by in the parks. We all sat around laughing and watching the lines formed by our hands as we waved them in front of our faces.” According to SE, these early experiences with hallucinogens brought about meaningful experiences to him. However, there were no eyes-closed effects on visual imagery.

While doing a PhD in psychology, he traveled to the Amazon region to try ayahuasca. Thirty minutes after ingesting a single dose, he began vomiting and described the experience of being physically in the Amazon jungle, but his mind was “back in the city”: “I saw my life being acted out in front of me as if I was watching a play from the balcony.” Suddenly his experience changed into fear, when he felt “spiraling through a colorful tunnel.” The healer started chanting and calmed him. With his eyes closed, he saw his father, who had passed away years ago: “I could see him clearly, hear his voice, and even smell the distinct smell that he picked up from working in the oil fields. I was seeing in visual imagery for the first time in my life as I laid there with my eyes closed.

SE then described a complex scene involving the difficult relationship that he had with his father, who left him when he was very young. This early separation seemed to be quite a traumatic and painful event to SE, who later developed a difficult relationship with his father: “My father left when I was too young to remember. My first memory of my father was seeing him years later and of him getting upset at me because I didn’t know who he was. My brother and I used to travel during the summer breaks to visit him. These visits were pleasant but short and, as I grew older, confusing. My father used to take me into grocery stores and put food into my clothes and walk out of the store without paying. He would tell me, my brother, and my step-brother to steal televisions from the store while he distracted the store clerk – and if we got caught he would punish us in front of the clerk. I have many similar stories, stories that made no sense to me, but their importance lies not in the facts but in the pain under the stories. We were never close, and when he eventually moved back to be closer with us, I was an angry teenager. This anger of course made me want to reject him, and his response was to put as much blame back on me as he could.

This difficult relationship persisted until the death of his father some years: “When I was 19 he was burned in a steam fire and developed a staph infection. We knew he was dying and one day after my classes at the local city college I visited him. I was alone with him and at this point he no longer was breathing on his own, and he lay there unresponsive. The nurse encouraged me to speak to him, saying that he could hear me, but I couldn’t say anything. I just sat there in the corner of the room watching his chest go up and down with the timing of the machine. I was young and didn’t know what to feel or how to process all of the mixed emotions. I left without saying a word or even touching him. The next day I was told that he had passed away.

SE then reported that he saw his grandfather in a peaceful place, but his father was in a state of agony since he “could not visit my grandfather because I had not released him from his guilt. My anger became evident to me and I felt it in all cells in my body. I didn’t realize it was still there after all these years. I was convinced I had dealt with it. But it was there, and it had control over me. My anger transformed into hurt, a feeling of abandonment overcame me, and then the feeling of worthlessness became stronger than ever.

The scene then developed into SE forgiving his father and accepting their differences: “My father pleaded for me, not to forgive him, but to forgive myself. He wanted me to know that none of what I felt was my fault and he opened himself up to make it all clear to me. I began to cry, and my father was finally able to move on to be with my grandfather. I had forgiven him; I had forgiven myself. A drum started to beat lightly, and it gradually intensified deep in my heart. This vibration overcame my entire body until I was chanting strongly aloud. I felt worthy. I felt like a good person. When I released my father from his guilt, he released me from my feelings of not being good.

After the experience, SE developed the ability to visualize: “I can now bring forth faint pictures in my mind. They fade quickly but they are there. When dreaming I now see faint, quickly fading images. It feels like this experience with ayahuasca has slightly opened up my mind’s eye and allowed me to experience internal images like I have never had before. Ayahuasca turned on my mind’s eye, even if it is faint.

While the authors have never met him personally, he approved and actively participated in the manuscript production. Since we did not know SE before his experience with ayahuasca, it was not possible to assess his imagery skills before that time. Thus, to have an idea of his experience, we asked SE to retrospectively answer the Vividness of Visual Imagery Questionnaire used by Zeman et al. (2015) in his research. SE answered the questionnaire in December 2017 and his score was 30, which, according to Zeman et al. (2015), would classify him in the “minimal imagery” group (score >16, range: 17–30), compared with the “no visual imagery” (score = 16) and control (score >57) groups. Although his score was no more than “minimal” group, SE felt that his imagery had improved, as reported above.

Discussion

Recent neuroimaging studies with LSD and psilocybin, agonists of cortical 5-HT2A/2C/1A receptors as DMT, suggest that imagery is heightened by these drugs. It seems that these drugs induce more parts of the brain to process visual information, and that the brain interprets these effects like “real” visual perceptions (Carhart-Harris et al., 2016; dos Santos et al., 2016; Roseman et al., 2016). Regarding ayahuasca, an open-label study showed that, during an imagery task, ayahuasca induced significant activation in the primary visual area comparable to the activation levels of a natural image with the eyes open (de Araujo et al., 2012).

It is interesting to note that SE reported previous use of other hallucinogens that act as 5-HT2A/2C/1A agonists, such as LSD and psilocybin, but improvements in his aphantasia were noticed only with ayahuasca. Although these drugs share a common pharmacological mechanism, SE reported that his previous experiences were meaningful but at the same time were restricted to visual alterations with opened eyes, and usually happened in public places, such as parks, suggesting recreational use. Although ayahuasca also has harmine and related beta-carbolines in its composition, the main role of these compounds in the human pharmacology of ayahuasca seems to be restricted to the reversible inhibition of peripheral monoamine oxidase, which renders oral DMT active. Moreover, it is highly unlikely that a single ayahuasca dose could have induced structural, permanent changes in SE’s brain.

Thus, another possible explanation could be related to non-pharmacological or environmental factors, such as the difference between the contexts where he had his experiences. For instance, ayahuasca was used in a ritual and therapeutic setting where SE experienced a meaningful curative experience that was emotionally intense and apparently cathartic. This experience was characterized not only by visual perceptions, but also by emotionally charged memories and insights, which seem to have caused a psychological change in him. Those aspects were not present in his experiences with LSD and psilocybin, which were used in recreational contexts and did not cause meaningful or emotionally intense feelings in him. Therefore, it is plausible to speculate that his absence of voluntary imagery was related to a confused relation with his father and thus to a psychological origin, especially when we consider his statement: “I traveled back in time through my visual memory and discovered the traumatic moment in which the mind’s eye closed.” Moreover, SE reported that “… in moments in which I feel most centered, most confident in myself, the most sure of my path, is when the images are strongest.

The last possibility is that SE was depressed and/or had posttraumatic stress disorder (PTSD), and ayahuasca could have caused an antidepressant response in him (Palhano-Fontes et al., 2018; Sanches et al., 2016). Thus, we could speculate that the trauma could have induced a functional deficit that was resolved by ayahuasca. However, this is unlikely because SE did not report depressive or PTSD symptoms.

Considering that aphantasia has a low incidence but is usually lifelong and no treatment is available, future research should assess if people with aphantasia may improve after using ayahuasca or other serotonergic hallucinogens. Future studies should also assess whether aphantasia is due to trauma or something else (such as functional changes in brain dynamics), so that the theory proposed here can be tested.

Acknowledgements

The authors would like to thank SE for allowing us to report his case and for participating in the manuscript production.

Conflict of interest

RGdS is Fellow of the Brazilian National Post-Doctorate Program (PNPD/CAPES) and member of the ICEERS Advisory Board. JCB and OP are ICEERS employees or collaborators. ICEERS is a non-profit organization that promotes the scientific research of ayahuasca. JECH receives a CNPq (Brazil) Productivity Fellowship Award. For the remaining authors, none were declared. None of the authors received any specific funding for participating in this investigation. All authors had full access to all the data and had final responsibility for the decision to submit for publication.

References

  • Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., Leech, R., Williams, L. T., Williams, T. M., Bolstridge, M., Sessa, B., McGonigle, J., Sereno, M. I., Nichols, D., Hellyer, P. J., Hobden, P., Evans, J., Singh, K. D., Wise, R. G., Curran, H. V., Feilding, A., & Nutt, D. J. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences of the United States of America, 113(17), 48534858. doi:10.1073/pnas.1518377113

    • Crossref
    • Search Google Scholar
    • Export Citation
  • de Araujo, D. B., Ribeiro, S., Cecchi, G. A., Carvalho, F. M., Sanchez, T. A., Pinto, J. P., de Martinis, B. S., Crippa, J. A., Hallak, J. E., & Santos, A. C. (2012). Seeing with the eyes shut: Neural basis of enhanced imagery following ayahuasca ingestion. Human Brain Mapping, 33(11), 25502560. doi:10.1002/hbm.21381

    • Crossref
    • Search Google Scholar
    • Export Citation
  • de Vito, S., & Bartolomeo, P. (2016). Refusing to imagine? On the possibility of psychogenic aphantasia. A commentary on Zeman et al. (2015). Cortex, 74, 334335. doi:10.1016/j.cortex.2015.06.013

    • Crossref
    • Search Google Scholar
    • Export Citation
  • dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016). Classical hallucinogens and neuroimaging: A systematic review of human studies. Neuroscience and Biobehavioral Reviews, 71, 715728. doi:10.1016/j.neubiorev.2016.10.026

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Gallagher, J. (2015). Aphantasia: A life without mental images. Retrieved from http://www.bbc.com/news/health-34039054 (accessed on: April 12, 2018).

    • Search Google Scholar
    • Export Citation
  • Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M., Pessoa, J., Mota-Rolim, S., Osório, F. L., Sanches, R., dos Santos, R. G., Tofoli, L., Silveira, G., Yonamine, M., Riba, J., Santos, F. R. R., Silva-Junior, A. A., Alchieri, J., Galvao-Coelho, N., Lobao-Soares, B., Hallak, J., Arcoverde, E., Maia-de-Oliveira, J., & de Araujo, D. B. (2018). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomised placebo-controlled trial. Psychological Medicine. Advance online publication. doi:10.1017/S0033291718001356.

    • Search Google Scholar
    • Export Citation
  • Roseman, L., Sereno, M. I., Leech, R., Kaelen, M., Orban, C., McGonigle, J., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2016). LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion. Human Brain Mapping, 37(8), 30313040. doi:10.1002/hbm.23224

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Sanches, R. F., Osório, F., dos Santos, R. G., Macedo, L. R., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2016). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study. Journal of Clinical Psychopharmacology, 36(1), 7781. doi:10.1097/JCP.0000000000000436

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Schultes, R. E., & Hofmann, A. (1992). Plants of the gods: Their sacred, healing, and hallucinogenic powers. Rochester, VT: Healing Arts Press.

    • Search Google Scholar
    • Export Citation
  • Zeman, A., Dewar, M., & Della Sala, S. (2015). Lives without imagery – Congenital aphantasia. Cortex, 73, 378380. doi:10.1016/j.cortex.2015.05.019

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Zeman, A., Dewar, M., & Della Sala, S. (2016). Reflections on aphantasia. Cortex, 74, 336337. doi:10.1016/j.cortex.2015.08.015

  • Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., Leech, R., Williams, L. T., Williams, T. M., Bolstridge, M., Sessa, B., McGonigle, J., Sereno, M. I., Nichols, D., Hellyer, P. J., Hobden, P., Evans, J., Singh, K. D., Wise, R. G., Curran, H. V., Feilding, A., & Nutt, D. J. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences of the United States of America, 113(17), 48534858. doi:10.1073/pnas.1518377113

    • Crossref
    • Search Google Scholar
    • Export Citation
  • de Araujo, D. B., Ribeiro, S., Cecchi, G. A., Carvalho, F. M., Sanchez, T. A., Pinto, J. P., de Martinis, B. S., Crippa, J. A., Hallak, J. E., & Santos, A. C. (2012). Seeing with the eyes shut: Neural basis of enhanced imagery following ayahuasca ingestion. Human Brain Mapping, 33(11), 25502560. doi:10.1002/hbm.21381

    • Crossref
    • Search Google Scholar
    • Export Citation
  • de Vito, S., & Bartolomeo, P. (2016). Refusing to imagine? On the possibility of psychogenic aphantasia. A commentary on Zeman et al. (2015). Cortex, 74, 334335. doi:10.1016/j.cortex.2015.06.013

    • Crossref
    • Search Google Scholar
    • Export Citation
  • dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016). Classical hallucinogens and neuroimaging: A systematic review of human studies. Neuroscience and Biobehavioral Reviews, 71, 715728. doi:10.1016/j.neubiorev.2016.10.026

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Gallagher, J. (2015). Aphantasia: A life without mental images. Retrieved from http://www.bbc.com/news/health-34039054 (accessed on: April 12, 2018).

    • Search Google Scholar
    • Export Citation
  • Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M., Pessoa, J., Mota-Rolim, S., Osório, F. L., Sanches, R., dos Santos, R. G., Tofoli, L., Silveira, G., Yonamine, M., Riba, J., Santos, F. R. R., Silva-Junior, A. A., Alchieri, J., Galvao-Coelho, N., Lobao-Soares, B., Hallak, J., Arcoverde, E., Maia-de-Oliveira, J., & de Araujo, D. B. (2018). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomised placebo-controlled trial. Psychological Medicine. Advance online publication. doi:10.1017/S0033291718001356.

    • Search Google Scholar
    • Export Citation
  • Roseman, L., Sereno, M. I., Leech, R., Kaelen, M., Orban, C., McGonigle, J., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2016). LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion. Human Brain Mapping, 37(8), 30313040. doi:10.1002/hbm.23224

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Sanches, R. F., Osório, F., dos Santos, R. G., Macedo, L. R., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2016). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study. Journal of Clinical Psychopharmacology, 36(1), 7781. doi:10.1097/JCP.0000000000000436

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Schultes, R. E., & Hofmann, A. (1992). Plants of the gods: Their sacred, healing, and hallucinogenic powers. Rochester, VT: Healing Arts Press.

    • Search Google Scholar
    • Export Citation
  • Zeman, A., Dewar, M., & Della Sala, S. (2015). Lives without imagery – Congenital aphantasia. Cortex, 73, 378380. doi:10.1016/j.cortex.2015.05.019

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Zeman, A., Dewar, M., & Della Sala, S. (2016). Reflections on aphantasia. Cortex, 74, 336337. doi:10.1016/j.cortex.2015.08.015

The author instruction is available in PDF.
Please, download the file from HERE

Book Review Guidelines are available from HERE.

 

Editor-in-Chief:

Attila Szabo - University of Oslo

E-mail address: attilasci@gmail.com

Associate Editors:

  • Per Carlbring - Stockholm University, Sweden
  • Alan K. Davis - The Ohio State University & Johns Hopkins University, USA
  • Zsolt Demetrovics - Eötvös Lóránd University, Budapest, Hungary
  • Ede Frecska, founding Editor-in-Chief - University of Debrecen, Debrecen, Hungary
  • David Luke - University of Greenwich, London, UK
  • Dennis J. McKenna- Heffter Research Institute, St. Paul, USA
  • Jeremy Narby - Swiss NGO Nouvelle Planète, Lausanne, Switzerland
  • Stephen Szára - Retired from National Institute on Drug Abuse, Bethesda, USA
  • Enzo Tagliazucchi - Latin American Brain Health Institute, Santiago, Chile, and University of Buenos Aires, Argentina
  • Michael Winkelman - Retired from Arizona State University, Tempe, USA 

Book Reviews Editor:

Michael Winkelman - Retired from Arizona State University, Tempe, USA

Editorial Board

  • Gábor Andrássy - University of Debrecen, Debrecen, Hungary
  • Tiago Arruda-Sanchez - Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
  • Paulo Barbosa - State University of Santa Cruz, Bahia, Brazil
  • Michael Bogenschutz - New York University School of Medicine, New York, NY, USA
  • Petra Bokor - University of Pécs, Pécs, Hungary
  • Jose Bouso - Autonomous University of Madrid, Madrid, Spain
  • Zoltán Brys - Multidisciplinary Soc. for the Research of Psychedelics, Budapest, Hungary
  • Susana Bustos - California Institute of Integral Studies San Francisco, USA
  • Robin Carhart-Harris - Imperial College, London, UK
  • Valerie Curran - University College London, London, UK
  • Alicia Danforth - Harbor-UCLA Medical Center, Los Angeles, USA
  • Rick Doblin - Boston, USA
  • Rafael G. dos Santos - University of Sao Paulo, Sao Paulo, Brazil
  • Genis Ona Esteve - Rovira i Virgili University, Spain
  • Silvia Fernandez-Campos
  • Zsófia Földvári - Oslo University Hospital, Oslo, Norway
  • Andrew Gallimore - University of Cambridge, Cambridge, UK
  • Neal Goldsmith - private practice, New York, NY, USA
  • Charles Grob - Harbor-UCLA Medical Center, Los Angeles, CA, USA
  • Stanislav Grof - California Institute of Integral Studies, San Francisco, CA, USA
  • Karen Grue - private practice, Copenhagen, Denmark
  • Jiri Horacek - Charles University, Prague, Czech Republic
  • Lajos Horváth - University of Debrecen, Debrecen, Hungary
  • Robert Jesse - Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Matthew Johnson - Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • István Kelemen - University of Debrecen, Debrecen, Hungary
  • Eli Kolp - Kolp Institute New, Port Richey, FL, USA
  • Stanley Krippner - Saybrook University, Oakland, CA, USA
  • Evgeny Krupitsky - St. Petersburg State Pavlov Medical University, St. Petersburg, Russia
  • Rafael Lancelotta - Innate Path, Lakewood, CO, USA
  • Anja Loizaga-Velder - National Autonomous University of Mexico, Mexico City, Mexico
  • Luis Luna - Wasiwaska Research Center, Florianópolis, Brazil
  • Katherine MacClean - Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Deborah Mash - University of Miami School of Medicine, Miami, USA
  • Friedericke Meckel - private practice, Zurich, Switzerland
  • Ralph Metzner - California Institute of Integral Studies, San Francisco, CA, USA
  • Michael Mithoefer - private practice, Charleston, SC, USA
  • Levente Móró - University of Turku, Turku, Finland
  • David Nichols - Purdue University, West Lafayette, IN, USA
  • David Nutt - Imperial College, London, UK
  • Torsten Passie - Hannover Medical School, Hannover, Germany
  • Janis Phelps - California Institute of Integral Studies, San Francisco, CA, USA
  • József Rácz - Semmelweis University, Budapest, Hungary
  • Christian Rätsch - University of California, Los Angeles, Los Angeles, CA, USA
  • Jordi Riba - Sant Pau Institute of Biomedical Research, Barcelona, Spain
  • Sidarta Ribeiro - Federal University of Rio Grande do Norte, Natal, Brazil
  • William Richards - Johns Hopkins School of Medicine, Baltimore, MD, USA
  • Stephen Ross - New York University, New York, NY, USA
  • Brian Rush - University of Toronto, Toronto, Canada
  • Eduardo Schenberg - Federal University of São Paulo, São Paulo, Brazil
  • Ben Sessa - Cardiff University School of Medicine, Cardiff, UK
  • Lowan H. Stewart - Santa Fe Ketamine Clinic, NM, USA (Medical Director)
  • Rebecca Stone - Emory University, Atlanta, GA, USA
  • Rick Strassman - University of New Mexico School of Medicine, Albuquerque, NM, USA
  • Attila Szabó - University of Oslo, Oslo, Norway
  • Csaba Szummer - Károli Gáspár University of the Reformed Church, Budapest, Hungary
  • Manuel Torres - Florida International University, Miami, FL, USA
  • Luís Fernando Tófoli - University of Campinas, Campinas, Brazil State
  • Malin Uthaug - Maastricht University, Maastricht, The Netherlands
  • Julian Vayne - Norwich, UK
  • Nikki Wyrd - Norwich, UK

Attila Szabo
University of Oslo

E-mail address: attilasci@gmail.com

Indexing and Abstracting Services:

  • APA PsycInfo
  • DOAJ
  • Scopus
  • CABELLS

2021  
Web of Science  
Total Cites
WoS
not indexed
Journal Impact Factor not indexed
Rank by Impact Factor

not indexed

Impact Factor
without
Journal Self Cites
not indexed
5 Year
Impact Factor
not indexed
Journal Citation Indicator not indexed
Rank by Journal Citation Indicator

not indexed

Scimago  
Scimago
H-index
2
Scimago
Journal Rank
not yet available
Scimago Quartile Score Anthropology (Q3)
Biological Psychiatry (Q4)
Clinical Psychology (Q4)
Health (social science) (Q4)
Pharmacology (medical) (Q4)
Psychiatry and Mental Health (Q4)
Social Psychology (Q4)
Scopus  
Scopus
Cite Score
0,9
Scopus
CIte Score Rank
Anthropology 186/443 (Q2)
Health (social science) 234/323 (Q3)
Clinical Psychology 213/292 (Q3)
Pharmacology (medical) 190/255 (Q3)
Psychiatry and Mental Health 419/529 (Q4)
Social Psychology 243/296 (Q4)
Biological Psychiatry 38/43 (Q4)
Scopus
SNIP
0,381

2020  
CrossRef Documents 8
WoS Cites 37
WoS H-index 4
Days from submission to acceptance 95
Days from acceptance to publication 75
Acceptance Rate 41%

2019  
WoS
Cites
11
CrossRef
Documents
35
Acceptance
Rate
77%

 

Journal of Psychedelic Studies
Publication Model Gold Open Access
Submission Fee none
Article Processing Charge none
Subscription Information Gold Open Access

Journal of Psychedelic Studies
Language English
Size A4
Year of
Foundation
2016
Volumes
per Year
1
Issues
per Year
2
Founder Akadémiai Kiadó
Debreceni Egyetem
Eötvös Loránd Tudományegyetem
Károli Gáspár Református Egyetem
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
H-4032 Debrecen, Hungary Egyetem tér 1.
H-1053 Budapest, Hungary Egyetem tér 1-3.
H-1091 Budapest, Hungary Kálvin tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 2559-9283 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2022 0 263 210
Feb 2022 0 243 195
Mar 2022 0 258 200
Apr 2022 0 386 230
May 2022 0 307 246
Jun 2022 0 194 152
Jul 2022 0 20 15